Skip to main content
NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD logo

NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · NSB ISIN · AU0000012973 LEI · 254900YGHQSAMJODKC85 ASX Professional, scientific and technical activities
Open in API
Filings indexed 398 across all filing types
Latest filing 2026-05-25 Investor Presentation
Country AU Australia
Listing ASX NSB

About NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD

https://www.neuroscientific.com

NeuroScientific Biopharmaceuticals Ltd is a clinical-stage drug development company focused on creating peptide-based therapeutics for neurodegenerative disorders and ocular diseases. The company’s primary research centers on its lead drug candidate, EmtinB, a synthetic peptide modeled after the active domain of the human protein metallothionein-II. EmtinB is designed to promote neuroprotection and neuroregeneration by activating specific cell signaling pathways that prevent cell death and stimulate the repair of damaged neurons. The company targets high-unmet-need conditions, including Alzheimer’s disease, Multiple Sclerosis, and various forms of optic nerve damage such as glaucoma and optic neuritis. By leveraging biological mechanisms that mimic natural physiological responses to injury, NeuroScientific Biopharmaceuticals aims to provide disease-modifying treatments that improve clinical outcomes for patients with central nervous system and ophthalmic pathologies.

Recent filings

Filing Released Lang Actions
Updated Presentation - Successful Results 16 pages 1.3MB
Investor Presentation Classification · 92% confidence The document is a slide-based deck titled “Investor Presentation May 2026,” containing company snapshot, market opportunity, clinical data, product pipeline, milestones, leadership, disclaimers, and forward‐looking statements. It is clearly an investor-facing presentation rather than a financial report, regulatory filing, or other announcement type. Hence, it aligns with the Investor Presentation category.
2026-05-25 English
Remarkable Results from Patients treated with StemSmart 5 pages 436.8KB
Regulatory Filings Classification · 85% confidence The document is an ASX announcement detailing clinical program results and outlining future trial plans for a biotech product. It is not a formal financial report (no audited statements, no fiscal year summary), nor a vote or board management change, nor a presentation slide deck. It is a general regulatory/market update to shareholders via the exchange. It does not qualify as an earnings release, dividend notice, capital change, or interim report. Therefore, it falls under the fallback category “Regulatory Filings” (RNS).
2026-05-25 English
Trading Halt 2 pages 407.1KB
Regulatory Filings Classification · 88% confidence The document is an ASX market announcement requesting a trading halt under Listing Rule 17.1. It contains no financial data, management changes, dividend details, or audit information. It is a routine regulatory announcement concerning trading status, thus best classified under the general Regulatory Filings category (RNS).
2026-05-24 English
Quarterly Activities/Appendix 4C Cash Flow Report 12 pages 760.1KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report for the Period Ended 31 March 2026' and contains detailed operational updates, clinical trial progress, manufacturing technology transfer, financial position, and corporate activities for the quarter. It includes substantive financial data such as cash position, expenses, and payments to related parties. The document is comprehensive and covers a period shorter than a full fiscal year, consistent with an interim or quarterly report. It is not merely an announcement or a brief summary, nor is it a transcript, audit, or governance document. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2026-04-29 English
StemSmart Manufacturing Scale-Up Transfer Advances 5 pages 453.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 17 March 2026 from NeuroScientific Biopharmaceuticals Limited. It discusses the commencement of a technology transfer manufacturing run for StemSmart™ at a contract manufacturer, Q-Gen, and outlines progress towards Phase 2 clinical trials. The content focuses on operational updates, manufacturing scale-up, clinical development strategy, and market potential. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate update on manufacturing and clinical trial progress rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. The document fits best as a Capital/Financing Update (CAP) because it relates to manufacturing scale-up and clinical trial preparation, which are key operational milestones relevant to capital and financing activities in biotech firms. Therefore, the classification is CAP with high confidence.
2026-03-16 English
Half Yearly Report and Accounts 24 pages 3.0MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'NeuroScientific Biopharmaceuticals Limited Appendix 4D' and covers the half-year ended 31 December 2025. It includes detailed financial statements such as the condensed consolidated statement of profit or loss, statement of financial position, statement of changes in equity, and cash flows. It also contains a Directors' Report, Auditor's Independence Declaration, and an Independent Auditor's Report. The presence of comprehensive financial data and analysis for a half-year period, along with the explicit mention of the 'Interim Report' and the half-year reporting period, indicates this is a half-year financial report. The document length is substantial (15,000 characters), and it contains actual financial statements, not just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-02-24 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.